Assessment of the percentage of full recombinant adeno-associated virus particles in a gene therapy drug using CryoTEM
Open Access
- 3 June 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (6) , e0269139
Abstract
In spite of continuous development of gene therapy vectors with thousands of drug candidates in clinical drug trials there are only a small number approved on the market today stressing the need to have characterization methods to assist in the validation of the drug development process. The level of packaging of the vector capsids appears to play a critical role in immunogenicity, hence an objective quantitative method assessing the content of particles containing a genome is an essential quality measurement. As transmission electron microscopy (TEM) allows direct visualization of the particles present in a specimen, it naturally seems as the most intuitive method of choice for characterizing recombinant adeno-associated virus (rAAV) particle packaging. Negative stain TEM (nsTEM) is an established characterization method for analysing the packaging of viral vectors. It has however shown limitations in terms of reliability. To overcome this drawback, we propose an analytical method based on CryoTEM that unambiguously and robustly determines the percentage of filled particles in an rAAV sample. In addition, we show that at a fixed number of vector particles the portion of filled particles correlates well with the potency of the drug. The method has been validated according to the ICH Q2 (R1) guidelines and the components investigated during the validation are presented in this study. The reliability of nsTEM as a method for the assessment of filled particles is also investigated along with a discussion about the origin of the observed variability of this method.Keywords
Funding Information
- Baxalta Innovations GmbH, a part of Takeda companies
- Vironova AB
This publication has 42 references indexed in Scilit:
- Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effectsMolecular Therapy - Methods & Clinical Development, 2014
- Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia BInternational Journal of Hematology, 2013
- Defining Severity of Hemophilia: More than Factor LevelsSeminars in Thrombosis and Hemostasis, 2013
- Overcoming Preexisting Humoral Immunity to AAV Using Capsid DecoysScience Translational Medicine, 2013
- Virus-mediated gene delivery for human gene therapyJournal of Controlled Release, 2012
- Analysis of Particle Content of Recombinant Adeno-Associated Virus Serotype 8 Vectors by Ion-Exchange ChromatographyHuman Gene Therapy Methods, 2012
- Good Manufacturing Practice Production of Self-Complementary Serotype 8 Adeno-Associated Viral Vector for a Hemophilia B Clinical TrialHuman Gene Therapy, 2011
- Production and characterization of adeno-associated viral vectorsNature Protocols, 2006
- Novel Tools for Production and Purification of Recombinant Adenoassociated Virus VectorsHuman Gene Therapy, 1998
- Cryo-electron microscopy of virusesNature, 1984